NCT00030849View on ClinicalTrials.gov

Bexarotene and Interferon Alfa in Treating Patients With Cutaneous T-Cell Lymphoma

PHASE2CompletedINTERVENTIONAL
Timeline

Start Date

October 31, 2001

Primary Completion Date

September 30, 2004

Study Completion Date

December 31, 2009

Conditions
Lymphoma
Interventions
BIOLOGICAL

recombinant interferon alfa

DRUG

bexarotene

Trial Locations (5)

10016

NYU School of Medicine's Kaplan Comprehensive Cancer Center, New York

10021

Memorial Sloan-Kettering Cancer Center, New York

33136

University of Miami Sylvester Comprehensive Cancer Center, Miami

19104-4283

Abramson Cancer Center of the University of Pennsylvania Medical Center, Philadelphia

77030-4009

University of Texas - MD Anderson Cancer Center, Houston

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Memorial Sloan Kettering Cancer Center

OTHER

NCT00030849 - Bexarotene and Interferon Alfa in Treating Patients With Cutaneous T-Cell Lymphoma | Biotech Hunter | Biotech Hunter